Project Grant HT94252510225
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$952K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...
The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
The federal Project Grant award, valued at $2,490,000.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is for the "Development of a VAV2 Antisense Oligonucleotide Therapeutic for ALS" at the University of Southern California (USC). This award, effective March 1, 2025 through February 28, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
This federal Project Grant award for $3,854,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Massachusetts Medical School (UMass Medical) to target human respiratory viruses and host sequences with respiratory-active RNAs. The award, which runs from September 1, 2025 to August 31, 2029, supports advanced biomedical research aimed at transforming healthcare for military service...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,078,882 to the Sanford Burnham Prebys Medical Discovery Institute to conduct advanced chemical engineering research on amyotrophic lateral sclerosis (ALS). The research aims to take a more sophisticated, multimodal approach to understanding the therapeutic actions of donor and host neural stem cells in ALS. The award includes a sub-grant to the J. David...